New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
09:35 EDTCG, WLT, GILD, C, SIRI, GE, AAPL, ANV, DISH, MCRSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD MCRS GE WLT DISH SIRI CG ANV C
News For AAPL;GILD;MCRS;GE;WLT;DISH;SIRI;CG;ANV;C From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
July 16, 2015
06:58 EDTAAPLApple applies for patent for wireless devices with solar cells
Subscribe for More Information
06:46 EDTAAPLApple Watch to roll out in New Zealand July 31, AppleInsider reports
Subscribe for More Information
05:56 EDTDISHNetflix ruling irrelevant to Rovi contract renewals, says B. Riley
Subscribe for More Information
05:52 EDTDISHRuling in Netflix case a negative for Rovi, says JPMorgan
JPMorgan analyst Sterling Auty says court filings released after yesterday's market close indicate Netflix (NFLX) was granted a motion of summary invalidating all five of the remaining Rovi (ROVI) patents that were being contested. Auty expects Rovi to sell off on the news as investors consider what the ruling may do to the company's upcoming contract renewals with Comcast (CMCSA), Time Warner Cable (TWC), DirecTV (DTV) and DISH (DISH). The "big 4" choosing to litigate against Rovi is "certainly a possibility," but the companies have bigger patent infringement exposures than an over-the-top vendor like Netflix, Auty writes in a research note. He keeps a Neutral rating on Rovi.
July 15, 2015
16:00 EDTC, AAPLOptions Update; July 15, 2015
Subscribe for More Information
15:27 EDTCCiti July 56.5 straddle priced for 2.4% movement into Q2
14:53 EDTCNotable companies reporting before tomorrow's open
Subscribe for More Information
14:05 EDTCCiti reports June credit loss 2.49% vs. 2.86% last month
Subscribe for More Information
13:56 EDTCEarnings Watch: Analysts mixed on Citi after settlements, asset sales
Subscribe for More Information
13:50 EDTCEarnings Watch: Goldman Sachs to report after last quarter's earnings beat
Subscribe for More Information
13:01 EDTGEGeneral Electric secures orders for 10 LMS100 gas turbines
GE announced that it has secured 10 orders of its LMS100 aeroderivative gas turbine with two customers in North America in 2Q 2015. These recent successes have resulted in the backlog for LMS100 technology to be in excess of $450 million for GE Power & Water's Distributed Power business. The 10 units—five LMS100-PA gas turbine units and five LMS100-PA+ gas turbine units—have been ordered by two American customers.
12:38 EDTAAPLGundlach says out of Apple position
Subscribe for More Information
11:01 EDTAAPLApple introduces new iPod touch, unveils new colors for iPod models
Subscribe for More Information
10:16 EDTGEU.S. Bancorp sees growth in payments in 2H
Subscribe for More Information
10:00 EDTGEGeneral Electric signs $80M agreement with Emera Energy
Subscribe for More Information
09:53 EDTAAPLHSBC UK says Apple Pay support coming within 2 weeks, Apple Insider says
HSBC UK (HSBC) said that Apple Pay (AAPL) support is in its final testing and availability will be coming within two weeks, reports Apple Insider. An HSBC spokesperson said, "We are excited to be one of a small number of Apple Pay launch partners. We have been working closely with Apple and are now properly reviewing and testing our systems before launching in two weeks." Reference Link
09:32 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC RCPT MU YUM NFLX CELG
07:58 EDTGILDAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
06:39 EDTAAPLApple to release new iPod touch, 9to5Mac reports
Subscribe for More Information
06:33 EDTAAPLApple 'in touch' with Iranian distributors to sell products there, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use